Working… Menu

Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02262637
Recruitment Status : Completed
First Posted : October 13, 2014
Last Update Posted : October 13, 2014
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Study to evaluate efficacy and tolerability of Micardis®/MicardisPlus® under usual daily-practice prescribing-conditions with emphasis on effects on endorgan damage in the clientele of cardiologists, nephrologists, and diabetologists

Condition or disease Intervention/treatment
Hypertension Drug: Micardis® Drug: MicardisPlus®

Layout table for study information
Study Type : Observational
Actual Enrollment : 4814 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Micardis® / MicardisPlus® PROTEKT (Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases)
Study Start Date : September 2003
Actual Primary Completion Date : March 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Telmisartan

Group/Cohort Intervention/treatment
Hypertensive patients - Cardiologists Drug: Micardis®
Drug: MicardisPlus®
Hypertensive patients - Nephrologists Drug: Micardis®
Drug: MicardisPlus®
Hypertensive patients - Diabetologists Drug: Micardis®
Drug: MicardisPlus®

Primary Outcome Measures :
  1. Change in systolic blood pressure (SBP) [ Time Frame: baseline, up to 6 months ]
  2. Change in diastolic blood pressure (DBP) [ Time Frame: baseline, up to 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Outpatients with hypertension recruited at Cardiologists, Nephrologists, Diabetologists

Inclusion Criteria:

  • Age >= 18 years

Exclusion Criteria:

  • Age < 18 years

Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim Identifier: NCT02262637     History of Changes
Other Study ID Numbers: 502.441
502.442, 502.443 ( Other Identifier: Boehringer Ingelheim )
First Posted: October 13, 2014    Key Record Dates
Last Update Posted: October 13, 2014
Last Verified: October 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Telmisartan, hydrochlorothiazide drug combination
Cardiovascular Diseases
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators
Natriuretic Agents
Physiological Effects of Drugs